ZHAOKE OPHTH-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2024
ZHAOKE OPHTH-B: NOTIFICATION LETTER TO REGISTERED SHAREHOLDERS AND REPLY FORM
ZHAOKE OPHTH-B: NOTIFICATION LETTER TO NON-REGISTERED SHAREHOLDERS AND REPLY FORM
ZHAOKE OPHTH-B: FORM OF PROXY FOR USE AT THE ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, MAY 17, 2024
ZHAOKE OPHTH-B: Environmental, Social and Governance Report 2023
ZHAOKE OPHTH-B: LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION
ZHAOKE OPHTH-B: RESIGNATION OF NON-EXECUTIVE DIRECTOR
ZHAOKE OPHTH-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2024
ZHAOKE OPHTH-B: Letter to Registered Shareholders - Arrangement for Electronic Dissemination of Corporate Communications and Reply Form
ZHAOKE OPHTH-B: Letter to Registered Shareholders - Arrangement for Electronic Dissemination of Corporate Communications and Reply Form
ZHAOKE OPHTH-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 29 February 2024
ZHAOKE OPHTH-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2024
ZHAOKE OPHTH-B: VOLUNTARY ANNOUNCEMENT - ENTERING INTO DISTRIBUTION AGREEMENT WITH KWANGDONG PHARMACEUTICAL TO COMMERCIALIZE BRIMOCHOL PF IN THE REPUBLIC OF KOREA
ZHAOKE OPHTH-B: Voluntary Announcement - INVESTIGATIONAL NEW DRUG APPLICATIONS FOR CLINICAL TRIAL OF BRIMOCHOL PF AND CARBACHOL PF FOR THE TREATMENT OF PRESBYOPIA APPROVED BY NMPA
ZHAOKE OPHTH-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2023
ZHAOKE OPHTH-B: Monthly Return of Equity Issuer on Movements in Securities for the Month ended 30 November 2023
ZHAOKE OPHTH-B: LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION
ZHAOKE OPHTH-B: RESIGNATION OF NON-EXECUTIVE DIRECTOR AND CHANGE IN COMPOSITION OF THE AUDIT COMMITTEE
ZHAOKE OPHTH-B: Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 October 2023
ZHAOKE OPHTH-B: VOLUNTARY ANNOUNCEMENT - POSITIVE TOP-LINE RESULTS FROM NVK002 ONE-YEAR PHASE III CLINICAL TRIAL (MINI-CHAMP) IN CHINA FOR THE TREATMENT OF MYOPIA PROGRESSION IN CHILDREN
No Data